Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Boehringer Ingelheim GmbH : Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional’s FX125L and the somatotaxin portfolio to treat inflammation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/23/2012 | 11:04am CEST

Ingelheim, Germany and Cambridge, UK - 23 July 2012 Today, Boehringer Ingelheim, one of the world's leading pharmaceutical companies, and Funxional Therapeutics, a clinical-stage, asset-centric, private company, announced an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics' FX125L compound and somatotaxin programme. FX125L is a small molecule to treat a broad range of inflammatory diseases and was recently studied in a Phase 2 clinical trial in patients. Boehringer Ingelheim will be responsible for all further research, development and commercialisation of FX125L. Financial details of the transaction were not disclosed.

"Boehringer Ingelheim is delighted to add another promising compound to its development pipeline of drugs for the treatment of respiratory disease, one of its most important therapeutic areas", said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, "by acquiring the Funxional Therapeutics programme, we are looking forward to bringing a potential new therapy to patients, for instance those suffering from Asthma and COPD."

David Grainger, Founder and CSO of Funxional Therapeutics commented: "We are very pleased that the future development of FX125L and the somatotaxin programme will be now driven forward by Boehringer Ingelheim. They are a very impressive organisation and their people have the necessary knowledge, skills and experience to successfully develop FX125L."

Funxional Therapeutics was founded by David Grainger with initial investment from Index Ventures and Novo A/S in 2006. Ventech led the Series B financing. Index Ventures' partner and Chairman of the board, Michele Ollier said: "This acquisition is further validation of Index's business model and we congratulate the team who have delivered first class science and developed a very exciting molecule. They have done an extraordinary job of building this company."

Notes for Editors

About Somatotaxins
The somatotaxins are a new class of anti-inflammatory small molecules that exploit a new pathway discovered by FXT. This novel pathway is acting through the type-2 somatostatin receptor involved in the resolution of inflammation, and disrupted in chronic inflammatory diseases including asthma, COPD and rheumatoid arthritis. FXT's portfolio of somatotaxins exploit this pathway to deliver broad and potent anti-inflammatory activity, with different compounds optimised for topical, parenteral and oral delivery.

About Funxional Therapeutics
Funxional Therapeutics Ltd (FXT) is a privately held, clinical stage pharmaceutical company based in Cambridge, UK.

FXT's focus is on novel anti-inflammatory therapies that exploit a new pathway discovered by FXT. The lead product (FX125L, an orally available, once-daily small molecule which belongs to the new class of somatotaxins) has completed several Phase I studies in the USA. Attractive efficacy compared to existing therapeutic options, together with an adequate safety profile and dosing convenience, all position FX125L for clinical and commercial differentiation, with the potential eventually to become the first line therapy in major inflammatory diseases. Funxional Therapeutics was founded in 2005 based on intellectual property developed by Dr David Grainger and his colleagues at Cambridge University, in collaboration with Ipsen, a global specialty-driven pharmaceutical company targeting debilitating diseases in neurology, endocrinology, uro-oncology and hemophilia. Index Ventures and Novo A/S provided first round funding to initiate research and development activities. Further funding was led by Ventech.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
02:38p HARVEY NORMAN : Apple iPhone 7 akan dilancarkan pada 12 September ini
02:28p ARAB BANK : profits hit $206.6m in Q2
02:28p Major events on Tadawul this week
02:25p FOSUN : Progress update announcement - in relation to a possible ipo of ironshore inc
02:25p COLOUR LIFE SERVICES : List Of Directors And Their Roles And Functions
02:25p COLOUR LIFE SERVICES : Resignation of executive director and chief financial officer, appointment of chief financial officer and change of company secretary and authorised representative
02:25p KINGDOM HOLDING 5.8% OWNER OF ACCORHOTELS FOLLOWING COMBINATION OF FRHI PLATFORM IN A $3.2 BILLION ENTERPRISE VALUE DEAL. PRINCE ALWALEED : “KHC is now a significant shareholder in a global platform with over 4,000 hotels and 560,000 rooms”
02:25p ITIDA INFORMATION TECHNOLOGY INDUSTRY DEVELOPMEN : China Delegation Visits ITIDA to Discuss ICT Cooperation
02:25p BANK OF SHARJAH J S C : 24 Jul 2015 - Management Discussion & Analysis Report Bank of Sharjah for the period ending June 30 2016
02:25p YUZHOU PROPERTIES : Announcements and Notices - Grant of Waiver under Rule 14.41(a) of the Listing Rules
Latest news
Advertisement
Hot News 
4.80%STANLEY BLACK & DECKER : Names New CEO, Raises Guidance
-6.75%PAYPAL : Visa profit tops estimates on higher payments volume
-2.57%HONEYWELL : Cuts Revenue Guidance
11.88%ADVANCED MICRO DEVICES : Correction to AMD earnings article
8.51%TSX at highest close in year, 4th weekly gain; telecoms shine
Most Read News
12:30a ASEAN ASSOCIATION OF SOUTH EAST ASIAN NATIONS : Welcoming Remarks by H.E. Saleumxay KOMMASITH, Minister of Foreign Affairs of the Lao PDR at the Opening Ceremony of the 49th ASEAN Foreign Ministers’ Meeting
12:08a VOLKSWAGEN : No More Diesel Cars for US, Says Volkswagen
07/23 MANCHESTER UNITED : Sunderland snap up 'first choice' Moyes as boss
07/23 EXCLUSIVE : Tesla, SolarCity close to merger agreement
07/23 MICROSOFT : will spend up to $2.5B for 1.7M square-foot data center in Iowa, its largest in U.S.
Most recommended articles
08:16a Spain poised to grow 2.9 percent in 2016 -Economy Minister
07:53a Melker Schorling, Sweden's quiet tycoon with the Midas touch
07:10a ROBERT STEWART : Ex-Wall Street banker accused of insider tips to father faces trial
06:42a Corporate raiders seek Brexit bargains in Britain
05:45aDJMICHAEL DELL : Dell, HP Take Opposite Tacks Amid Roiling Tech Market